Bezlotoxumab + Placebo + Antibacterial drug treatment (ABD)
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Clostridium Difficile Infection
Conditions
Clostridium Difficile Infection
Trial Timeline
Mar 27, 2018 → May 12, 2022
NCT ID
NCT03182907About Bezlotoxumab + Placebo + Antibacterial drug treatment (ABD)
Bezlotoxumab + Placebo + Antibacterial drug treatment (ABD) is a phase 3 stage product being developed by Merck for Clostridium Difficile Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT03182907. Target conditions include Clostridium Difficile Infection.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03182907 | Phase 3 | Completed |
Competing Products
20 competing products in Clostridium Difficile Infection